Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges:
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Erlangen
Friedrich-Alexander-Universität Erlangen-Nürnberg
2017
|
| Schlagworte: | |
| Online-Zugang: | Volltext Volltext Volltext |
| Beschreibung: | Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich |
| Beschreibung: | 1 Online-Ressource |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046039610 | ||
| 003 | DE-604 | ||
| 005 | 20190724 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190709s2017 gw |||| o||u| ||||||eng d | ||
| 015 | |a 19,O07 |2 dnb | ||
| 016 | 7 | |a 118888767X |2 DE-101 | |
| 024 | 7 | |a urn:nbn:de:bvb:29-opus4-111799 |2 urn | |
| 035 | |a (OCoLC)1111898378 | ||
| 035 | |a (DE-599)DNB118888767X | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE-BY | ||
| 049 | |a DE-29 | ||
| 084 | |a 610 |2 sdnb | ||
| 100 | 1 | |a Vetter, Marcel |d 1987- |e Verfasser |0 (DE-588)1103478494 |4 aut | |
| 245 | 1 | 0 | |a Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges |c Marcel Vetter, Markus F. Neurath |
| 264 | 1 | |a Erlangen |b Friedrich-Alexander-Universität Erlangen-Nürnberg |c 2017 | |
| 300 | |a 1 Online-Ressource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich | ||
| 583 | 1 | |a Archivierung/Langzeitarchivierung gewährleistet |5 DE-101 |2 pdager | |
| 653 | |a filgotinib | ||
| 653 | |a fingolimod | ||
| 653 | |a inflammatory bowel diseases | ||
| 653 | |a mongersen | ||
| 653 | |a oral therapy | ||
| 653 | |a ozanimod | ||
| 653 | |a phosphatidylcholine | ||
| 653 | |a tofacitinib | ||
| 700 | 1 | |a Neurath, Markus |d 1965- |e Verfasser |0 (DE-588)115599444 |4 aut | |
| 787 | 0 | 8 | |i Sonderdruck aus |t Therapeutic Advances in Gastroenterology |g 10 (2017), Seite 773 - 790 |o 10.1177/1756283X17727388 |
| 856 | 4 | 0 | |u https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-111799 |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://d-nb.info/118888767X/34 |x Langzeitarchivierung Nationalbibliothek |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://open.fau.de/handle/openfau/11179 |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ebook | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031421330 | ||
| 347 | |b PDF | ||
Datensatz im Suchindex
| _version_ | 1804180297108946944 |
|---|---|
| any_adam_object | |
| author | Vetter, Marcel 1987- Neurath, Markus 1965- |
| author_GND | (DE-588)1103478494 (DE-588)115599444 |
| author_facet | Vetter, Marcel 1987- Neurath, Markus 1965- |
| author_role | aut aut |
| author_sort | Vetter, Marcel 1987- |
| author_variant | m v mv m n mn |
| building | Verbundindex |
| bvnumber | BV046039610 |
| collection | ebook |
| ctrlnum | (OCoLC)1111898378 (DE-599)DNB118888767X |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02002nmm a2200505zc 4500</leader><controlfield tag="001">BV046039610</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20190724 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190709s2017 gw |||| o||u| ||||||eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">19,O07</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">118888767X</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">urn:nbn:de:bvb:29-opus4-111799</subfield><subfield code="2">urn</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1111898378</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB118888767X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BY</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Vetter, Marcel</subfield><subfield code="d">1987-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1103478494</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges</subfield><subfield code="c">Marcel Vetter, Markus F. Neurath</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Erlangen</subfield><subfield code="b">Friedrich-Alexander-Universität Erlangen-Nürnberg</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich</subfield></datafield><datafield tag="583" ind1="1" ind2=" "><subfield code="a">Archivierung/Langzeitarchivierung gewährleistet</subfield><subfield code="5">DE-101</subfield><subfield code="2">pdager</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">filgotinib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fingolimod</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammatory bowel diseases</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mongersen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oral therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ozanimod</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phosphatidylcholine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tofacitinib</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Neurath, Markus</subfield><subfield code="d">1965-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)115599444</subfield><subfield code="4">aut</subfield></datafield><datafield tag="787" ind1="0" ind2="8"><subfield code="i">Sonderdruck aus</subfield><subfield code="t">Therapeutic Advances in Gastroenterology</subfield><subfield code="g">10 (2017), Seite 773 - 790</subfield><subfield code="o">10.1177/1756283X17727388</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-111799</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://d-nb.info/118888767X/34</subfield><subfield code="x">Langzeitarchivierung Nationalbibliothek</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://open.fau.de/handle/openfau/11179</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031421330</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="b">PDF</subfield></datafield></record></collection> |
| id | DE-604.BV046039610 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:33:31Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031421330 |
| oclc_num | 1111898378 |
| open_access_boolean | 1 |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | 1 Online-Ressource |
| psigel | ebook |
| publishDate | 2017 |
| publishDateSearch | 2017 |
| publishDateSort | 2017 |
| publisher | Friedrich-Alexander-Universität Erlangen-Nürnberg |
| record_format | marc |
| spelling | Vetter, Marcel 1987- Verfasser (DE-588)1103478494 aut Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges Marcel Vetter, Markus F. Neurath Erlangen Friedrich-Alexander-Universität Erlangen-Nürnberg 2017 1 Online-Ressource txt rdacontent c rdamedia cr rdacarrier Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich Archivierung/Langzeitarchivierung gewährleistet DE-101 pdager filgotinib fingolimod inflammatory bowel diseases mongersen oral therapy ozanimod phosphatidylcholine tofacitinib Neurath, Markus 1965- Verfasser (DE-588)115599444 aut Sonderdruck aus Therapeutic Advances in Gastroenterology 10 (2017), Seite 773 - 790 10.1177/1756283X17727388 https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-111799 Resolving-System kostenfrei Volltext http://d-nb.info/118888767X/34 Langzeitarchivierung Nationalbibliothek kostenfrei Volltext https://open.fau.de/handle/openfau/11179 Verlag kostenfrei Volltext |
| spellingShingle | Vetter, Marcel 1987- Neurath, Markus 1965- Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges |
| title | Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges |
| title_auth | Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges |
| title_exact_search | Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges |
| title_full | Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges Marcel Vetter, Markus F. Neurath |
| title_fullStr | Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges Marcel Vetter, Markus F. Neurath |
| title_full_unstemmed | Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges Marcel Vetter, Markus F. Neurath |
| title_short | Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges |
| title_sort | emerging oral targeted therapies in inflammatory bowel diseases opportunities and challenges |
| url | https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-111799 http://d-nb.info/118888767X/34 https://open.fau.de/handle/openfau/11179 |
| work_keys_str_mv | AT vettermarcel emergingoraltargetedtherapiesininflammatoryboweldiseasesopportunitiesandchallenges AT neurathmarkus emergingoraltargetedtherapiesininflammatoryboweldiseasesopportunitiesandchallenges |